About the Study
Alzheimer’s disease can rob you of some of the best parts of your life. In order to put up a proper fight against this condition, more clinical research is sorely needed and that’s where the Clarity AD Study comes in. The main goals of the study are to assess the safety and efficacy of an investigational drug for Alzheimer’s disease.
The study will take place over the course of 24 months and consist of three phases: Screening, Treatment, and Follow Up. The study will enroll a total of 1566 participants. Participants who complete 18 months of core treatment may be eligible to receive open-label treatment (where all participants will receive the investigational drug) for up to 2 years.